Inactive Instrument

Company Yumanity Therapeutics

Equities

YMTX

US98872L1026

Business Summary

Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's pipeline consists of programs focused on Parkinson's disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. The Company's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The Company's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.

Number of employees: 41

Company contact information

Yumanity Therapeutics, Inc.

219 Terry Avenue North Suite 300

98109, Seattle

+

http://www.yumanity.com
address Yumanity Therapeutics(YMTX)

Sector

This company's sector is not yet available